Boehringer Ingelheim announced results from its Phase 3 trial of linagliptin for the treatment of type 2 diabetes. The new Phase 3 data found that linagliptin therapy resulted in significant reductions in HbA1c when compared to placebo, both when added to a sulfonylurea in patients with inadequately controlled type 2 diabetes or when administered as monotherapy in patients for whom metformin is inappropriate. Statistically significant differences in HbA1c between linagliptin and placebo could be seen at week 6 and week 18, the placebo adjusted mean difference was –0.57% (p<0.0001). Additionally, pharmacokinetic data demonstrated that decreases in renal function had minor effect on the elimination of linagliptin.
Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor being investigated as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
For more information call (800) 542-6257 or visit us.boehringer-ingelheim.com.